Skip to main content

Advertisement

SpringerLink
Log in

Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The aim was to compare the efficacy between doublets of third-generation agents (non-platinum) and doublets of platinum plus a third-generation agent (platinum-based) for chemotherapy-naïve advanced non-small-cell lung cancer (NSCLC).

Methods

We conducted a literature-based meta-analysis to compare the efficacy between doublets of third-generation agents and doublets of platinum plus a third-generation agent for chemotherapy-naïve advanced NSCLC. The primary end point was overall survival, and the secondary end points were progression-free survival (PFS) and response rate. Subgroup analyses were also conducted by different non-platinum doublet regimens or different platinum-based doublets. A descriptive review for toxicity was performed.

Results

Sixteen randomized controlled trials were identified ultimately. Results demonstrated that the efficacy of non-platinum doublets was comparable with platinum-based doublets according to the overall survival (HR = 1.03, 95 % CI = 0.98–1.08, p = 0.29). Subgroup analyses by different non-platinum doublets also showed the efficacy of all the third-generation doublets, such as vinorelbine plus gemcitabine, vinorelbine plus paclitaxel, gemcitabine plus paclitaxel, and gemcitabine plus docetaxel, was comparable with platinum-based doublets (HR = 1.00, 95 % CI = 0.78–1.27, p = 0.98; HR = 0.97, 95 % CI = 0.80–1.18, p = 0.79; HR = 1.05, 95 % CI = 0.99–1.12, p = 0.11; HR = 1.01, 95 % CI = 0.92–1.10, p = 0.87; respectively). Subgroup analyses by different platinum-based doublets indicated that the efficacy of the third-generation doublets were equal to both cisplatin-based doublets and carboplatin-based doublets (HR = 1.08, 95 % CI = 1.00–1.17, p = 0.05; HR = 1.00, 95 % CI = 0.94–1.05, p = 0.94; respectively). The secondary end points indicated that platinum-based doublets might have an advantage in PFS but not in response rate (HR = 1.06, 95 % CI = 1.01–1.12, p = 0.03; RR = 0.99, 95 % CI = 0.90–1.08, p = 0.81; respectively).

Conclusions

Non-platinum doublets were as effective as platinum-based doublets with different toxicity profile for chemotherapy-naïve advanced NSCLC in the era of third-generation agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M et al (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847–857

    Article  PubMed  CAS  Google Scholar 

  • Azzoli CG, Baker SJ, Temin S, Pao W, Aliff T, Brahmer J et al (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251–6266

    Article  PubMed  CAS  Google Scholar 

  • Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2:845–853

    Article  PubMed  Google Scholar 

  • Barata FJ, Parente B, Cunha J, Fernandes A, Figueiredo A, Conde S et al (2002) A phase II study, multicenter, randomized of carboplatin plus gemcitabine (CG) versus vinorelbine plus gemcitabine (VG) in advanced non small cell lung cancer (NSCLC) [abstract]. ESMO annual meeting. 523 p

  • Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

    Article  PubMed  CAS  Google Scholar 

  • Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM et al (2002) Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 13:108–115

    Article  PubMed  CAS  Google Scholar 

  • Chen S, Zhang J, Wang R, Luo X, Chen H (2010) The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70:63–70

    Article  PubMed  Google Scholar 

  • D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926–2936

    Article  PubMed  Google Scholar 

  • D’Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):S116–S119

    Article  Google Scholar 

  • Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  PubMed  CAS  Google Scholar 

  • Fløtten Ø, Bremnes RM, Grønberg BH, Sundstrøm S, Amundsen T, Rolke H et al (2010) Phase III study comparing vinorelbine/gemcitabine with vinorelbine/carboplatin as first-line chemotherapy of advanced NSCLC: a Norwegian Lung Cancer Study Group trial [abstract]. J Clin Oncol 15(suppl): abstr 7597

    Google Scholar 

  • Galvez C, Galmarini F (2000) Gemcitabine/cisplatin (G/P) vs gemcitabine/vinorelbine (G/V) in the treatment of non-small cell lung cancer (NSCLC): stage IIIB and IV abstract]. Ann Oncol 11(suppl 4):S115 (abstr 526P)

    Google Scholar 

  • Gamaz M, Taright TMS (2006) Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): preliminary results [abstract]. ASCO Annual Meeting Proceedings Part I 24(18S): abstr 17116

    Google Scholar 

  • Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A et al (2001a) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34(Suppl 4):S47–S51

    Article  PubMed  Google Scholar 

  • Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M et al (2001b) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478–1484

    Article  PubMed  CAS  Google Scholar 

  • Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945

    Article  PubMed  CAS  Google Scholar 

  • Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF et al (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3025–3034

    Article  PubMed  CAS  Google Scholar 

  • Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G et al (2009) Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14:497–510

    Article  PubMed  CAS  Google Scholar 

  • Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  Google Scholar 

  • Iwamoto Y, Saito H, Nakagawa K, Kashii T, Katakami N, Nakano T, et al (2007) A randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group 00 [abstract]. ASCO Annual Meeting Proceedings Part I 25(18S): abstr 18060

  • Jahnke K, Keilholz U, Luftner D, Thiel E, Schmittel A (2011) Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer. Anticancer Res 31:317–323

    PubMed  CAS  Google Scholar 

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  • Jiang J, Liang X, Zhou X, Huang R, Chu Z (2007) A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348–358

    Article  PubMed  Google Scholar 

  • Julian PTH, Douglas GA, Jonathan ACS (updated March 2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0. http://www.cochrane-handbook.org. Accessed 10 Feb 2012

  • Katakami N, Takiguchi Y, Yoshimori K, Isobe H, Bessho A, Yoshimura A et al (2006) Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 1:447–453

    Article  PubMed  Google Scholar 

  • Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J et al (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20:3578–3585

    Article  PubMed  CAS  Google Scholar 

  • Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D et al (2008) Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19:115–122

    Article  PubMed  CAS  Google Scholar 

  • Lilenbaum RC, Chen CS, Chidiac T, Schwarzenberger PO, Thant M, Versola M et al (2005) Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16:97–101

    Article  PubMed  CAS  Google Scholar 

  • Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909

    Article  Google Scholar 

  • Novello S, Le Chevalier T (2003) Chemotherapy for non-small-cell lung cancer. Part 1: early-stage disease. Oncology 17:357–364

    PubMed  Google Scholar 

  • Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834

    Article  PubMed  CAS  Google Scholar 

  • Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morère JF et al (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16:602–610

    Article  PubMed  Google Scholar 

  • Rigas JR, Carey M, Dragnev KH, Simeone SA, Page RD, Rubin MS et al (2008) Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): subgroup analysis from D0112 [abstract]. J Clin Oncol 26(15suppl): abstr 8100

    Google Scholar 

  • Rubio JC, Vazquez S, Vazquez F, Amenedo M, Fírvida JL, Mel JR et al (2009) A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 64:379–384

    Article  PubMed  CAS  Google Scholar 

  • Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol 21:3909–3917

    Article  PubMed  CAS  Google Scholar 

  • Solomon B, Bunn PA Jr (2005) Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treat Rev 31:571–576

    Article  PubMed  CAS  Google Scholar 

  • Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K et al (2004) Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 15:1048–1055

    Article  PubMed  CAS  Google Scholar 

  • Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K et al (2005) Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49:233–240

    Article  PubMed  CAS  Google Scholar 

  • Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM et al (2010) A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 21:540–547

    Article  PubMed  CAS  Google Scholar 

  • Walling J (1994) Chemotherapy for advanced non-small-cell lung cancer. Respir Med 88(649–657):18

    Google Scholar 

  • Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S et al (2006) West Japan Thoracic Oncology Group (WJTOG). Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer 107:599–605

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant number 81101551).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China

    Jingwei Jiang, Xiaohua Liang, Xinli Zhou, Ruofan Huang, Zhaohui Chu & Qiong Zhan

  2. Department of Oncology, Shanghai Medical College, Fudan University, No. 12 wulumuqi zhong road, Shanghai, 200040, China

    Jingwei Jiang, Xiaohua Liang, Xinli Zhou, Ruofan Huang, Zhaohui Chu & Qiong Zhan

Authors
  1. Jingwei Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaohua Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xinli Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ruofan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhaohui Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qiong Zhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xinli Zhou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiang, J., Liang, X., Zhou, X. et al. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents. J Cancer Res Clin Oncol 139, 25–38 (2013). https://doi.org/10.1007/s00432-012-1294-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-012-1294-z

Keywords

Search

Navigation